InsiderSignalSign in

← Insider buys

LQDA

Liquidia Corporation · Healthcare

Insiders bought $318K of Liquidia Corporation in the last 12 months

1 insider bought on 1 day.

$318KBought, 12 mo

$224.7MSold, 12 mo

$2.5BMarket cap

LQDA over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

Caligan Partners LPInsider · 1 day$318K

LQDA after insider buys

3 months after each buy, from the first price a copier could get.

+25.6%Average

+24.1 ptsVs S&P 500

9 of 13Higher

13 buys since 2018 with 3 months of prices.

Every filing

143 insider filings since 2018, newest first

Russell Schundler · General Counsel

$390K−2.2%Oct 13

Rajeev Saggar · Chief Medical Officer

$263K−6.8%Oct 13

Scott Moomaw · Chief Commercial Officer

$252K−4.7%Oct 13

Sarah Krepp · Chief Human Resource Officer

$149K−4.4%Oct 13

Sanjeev Khindri · Chief Development Officer

$31K−1.7%Oct 13

Michael Kaseta · CFO and COO

$539K−5.3%Oct 13

Roger Jeffs · Chief Executive Officer

$933K−2.8%Oct 13

Dana Boyle · Chief Accounting Officer

$168K−3.4%Oct 13

Jason Adair · Chief Business Officer

$208K−3.9%Oct 13

Stephen M Bloch · Director

$6.4M−100.0%Oct 7

Raman Singh · Director

$1.2M−28.2%Sep 15

Jason Adair · Chief Business Officer

$5.1M−29.7%Aug 25

Katherine Rielly-Gauvin · Director

$4.1M−55.3%Aug 21

Rajeev Saggar · Chief Medical Officer

$6.0M−35.9%Aug 19

Dana Boyle · Chief Accounting Officer

$140K−0.9%Jul 29

Jason Adair · Chief Business Officer

$60K−0.3%Jul 29

Stephen M Bloch · Director

$17.8M−28.5%Jul 24

Stephen M Bloch · Director

$6.3M−10.1%Jul 22

Sarah Krepp · Chief Human Resource Officer

$562K−6.3%Jul 15

Sanjeev Khindri · Chief Development Officer

$85K−1.8%Jul 15

Michael Kaseta · CFO and COO

$1.5M−5.6%Jul 15

Roger Jeffs · Chief Executive Officer

$2.5M−3.0%Jul 15

Jason Adair · Chief Business Officer

$562K−3.5%Jul 15

Russell Schundler · General Counsel

$1.1M−2.4%Jul 15

Rajeev Saggar · Chief Medical Officer

$710K−5.5%Jul 15

Scott Moomaw · Chief Commercial Officer

$682K−5.0%Jul 15

Dana Boyle · Chief Accounting Officer

$644K−5.0%Jul 14

Stephen M Bloch · Director

$6.1M−8.8%Jul 8

Stephen M Bloch · Director

$2.0M−2.8%Jul 6

Stephen M Bloch · Director

$7.6M−10.2%Jun 24

Stephen M Bloch · Director

$14.0M−16.7%Jun 16

Stephen M Bloch · Director

$26.6M−24.8%Jun 12

Sanjeev Khindri · Chief Development Officer

$271K−5.8%Jun 10

Stephen M Bloch · Director

$14.3M−12.4%Jun 10

Paul B Manning · Director

$12.8M−20.0%Jun 8

Stephen M Bloch · Director

$5.5M−4.5%Jun 8

Arthur S Kirsch · Director

$1.7M−100.0%Jun 3

Roger Jeffs · Chief Executive Officer

$400K−0.6%May 28

Raman Singh · Director

$1.8M−43.2%May 26

Roger Jeffs · Chief Executive Officer

$4.6M−6.7%May 26

Caligan Partners LP · Insider

Roger Jeffs · CEO

$4.4M−3.0%May 20

Roger Jeffs · CEO

$4.3M−3.0%May 15

Stephen M Bloch · Director

$16.0M−14.0%May 13

Roger Jeffs · Chief Executive Officer

$3.4M−5.6%May 12

Roger Jeffs · CEO

$3.1M−3.0%May 7

Dana Boyle · Chief Accounting Officer

$60K−1.0%Apr 29

Jason Adair · Chief Business Officer

Roger Jeffs · CEO

$765K−1.0%Apr 21

Roger Jeffs · CEO

$2.1M−2.0%Apr 16

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.